Please click here for UK prescribing information and adverse event reporting information
This is a promotional material fully funded by Bayer and is intended for UK healthcare professionals only. EYLEA (aflibercept) 8 mg is indicated in adults for the treatment of nAMD, visual impairment due to DMO and visual impairment due to macular oedema secondary to RVO (branch, central and hemiretinal RVO). Please refer to the licensed EYLEA 8 mg SmPC for the full licensed posology and the full summary of the safety profile.
UK real-world evidence
Select a region to reveal findings
-
NHS Greater Glasgow
and ClydenAMDPreviously treated39 eyesPost-loading phase -
Moorfields Eye Hospital,
Bedford Hospitals
NHS TrustnAMDTreatment-naïve26 eyes12 months -
The Royal Wolverhampton
NHS TrustnAMDTreatment-naïve &
previously treated86 eyes8−9 months -
University Hospitals
Bristol and Weston NHS
Foundation TrustnAMDTreatment-naïve96 eyes12 months -
University Hospitals of
Leicester NHS TrustnAMDPreviously treated126 eyes12 months
-
South Tyneside and
Sunderland NHS
Foundation TrustnAMDPreviously treated45 eyes12 months -
York and Scarborough
Teaching Hospitals NHS
Foundation TrustnAMDTreatment-naïve &
previously treated201 eyes12 months -
York and Scarborough
Teaching Hospitals NHS
Foundation TrustDMOTreatment-naïve &
previously treated48 eyes12 months -
Imperial College
Healthcare NHS TrustnAMDTreatment-naïve &
previously treated115 eyes12 months -
Imperial College
Healthcare NHS TrustDMOTreatment-naïve &
previously treated75 eyes12 months
Prescribing information
UK prescribing information and adverse event reporting information for EYLEA® (aflibercept) 40 mg/mL and 114.3 mg/mL solution for injection is available via the QR codes below. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.
EYLEA® (aflibercept)
40 mg/mL
EYLEA® (aflibercept)
114.3 mg/mL
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Bayer plc. If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.Further information is available on the "contact" tab at www.bayer.co.uk.
Produced and funded by Bayer.